Coherus 10-Q: Going-Concern Doubt With $83.6M Cash After $14.3M Q3 Revenue
CHRS is trading near its 52-week low of $0.732 (9.5% above the low).
Summary
Coherus's Q3 10-Q discloses substantial going-concern doubt, with $83.6 million of cash and securities against $154.0 million of nine-month operating cash burn, backstopped by a $55.0 million 2031 term loan and an untouched $50.0 million ATM.
Key Events · Earnings and Guidance · CHRS
-
Going-Concern Doubt Disclosed
Management concluded that substantial doubt about the ability to continue as a going concern had not been alleviated for the one-year period following issuance of the financial statements.
-
Cash Falls to $83.6 Million
Cash, cash equivalents and marketable securities totaled $83.6 million at September 30, 2026, versus $172.1 million at December 31, 2025, after $154.0 million of nine-month operating cash burn.
-
Q3 Revenue $14.3 Million
Total net revenue was $14.274 million for the quarter, with LOQTORZI contributing $14.009 million; nine-month revenue reached $40.891 million versus $29.424 million a year earlier.
-
Debt Refinanced Into 2031 Loan
The $55.0 million Innovatus Term A Loan was drawn August 14, 2026, repaying the 2029 Term Loan at a $41.2 million payoff and producing a $3.4 million loss on extinguishment; interest-only through September 2029.
Analysis · CHRS · Life Sciences
The 10-Q makes explicit what the earnings release only implied: management concluded that substantial doubt about Coherus's ability to continue as a going concern was not alleviated for the year following issuance. Cash, equivalents and marketable securities fell to $83.6 million from $172.1 million at year-end 2025, while the company burned $154.0 million of operating cash in nine months and carried a $1.5 billion accumulated deficit. The offset is the August refinancing — a $55.0 million Innovatus term loan maturing 2031 with interest-only payments for 36 months — plus a fresh $50.0 million Leerink ATM that has sold nothing yet. With LOQTORZI at $14.0 million for the quarter and a 30% headcount cut underway, the equity is now a bet on tagmokitug's esophageal cancer data and further capital raises.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CHRS was trading at $0.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $126.3M. The 52-week trading range was $0.73 to $2.62. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.